{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=60",
    "query": {
      "intervention": "Injectable Placebo",
      "page": 60
    },
    "page_size": 10
  },
  "pagination": {
    "page": 60,
    "page_size": 10,
    "total_count": 4216,
    "total_pages": 422,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=61&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=59&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T18:26:36.506Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03172910",
      "title": "Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ciraparantag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 69,
      "start_date": "2017-05-08",
      "completion_date": "2019-11-12",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-10-27T18:26:36.506Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172910"
    },
    {
      "nct_id": "NCT04589403",
      "title": "1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "OPT101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Op-T LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 14,
      "start_date": "2021-02-18",
      "completion_date": "2021-09-27",
      "has_results": false,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-10-27T18:26:36.506Z",
      "location_count": 1,
      "location_summary": "Centennial, Colorado",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04589403"
    },
    {
      "nct_id": "NCT05189210",
      "title": "GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild to Moderate Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "GV1001 Placebo",
          "type": "DRUG"
        },
        {
          "name": "GV1001 0.56mg",
          "type": "DRUG"
        },
        {
          "name": "GV1001 1.12mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GemVax & Kael",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 199,
      "start_date": "2022-10-05",
      "completion_date": "2025-04-16",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-10-27T18:26:36.506Z",
      "location_count": 12,
      "location_summary": "Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Adventura",
          "state": "Florida"
        },
        {
          "city": "Greenacres City",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05189210"
    },
    {
      "nct_id": "NCT00972062",
      "title": "Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Bach's Rescue Remedy Cream",
          "type": "OTHER"
        },
        {
          "name": "Placebo Cream",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Charlotte",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2009-06",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-07",
      "last_synced_at": "2026-10-27T18:26:36.506Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00972062"
    },
    {
      "nct_id": "NCT07059182",
      "title": "Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE",
        "Prevention of Pneumococcal-induced Acute Otitis Media"
      ],
      "interventions": [
        {
          "name": "Inactivated whole-cell Streptococcus pneumoniae vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Serum Life Science Europe GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-06-11",
      "completion_date": "2025-08-29",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-10-27T18:26:36.506Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07059182"
    },
    {
      "nct_id": "NCT04021862",
      "title": "A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Eczema"
      ],
      "interventions": [
        {
          "name": "Bermekimab Monoclonal Antibody",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2019-10-16",
      "completion_date": "2020-11-19",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-10-27T18:26:36.506Z",
      "location_count": 17,
      "location_summary": "Huntington Beach, California • Coral Gables, Florida • Doral, Florida + 11 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04021862"
    },
    {
      "nct_id": "NCT01221597",
      "title": "Study of AA4500 in the Treatment of Peyronie's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Peyronie's Disease"
      ],
      "interventions": [
        {
          "name": "AA4500",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Endo USA Inc., a Keenova Therapeutics Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 418,
      "start_date": "2010-09",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2017-10-05",
      "last_synced_at": "2026-10-27T18:26:36.506Z",
      "location_count": 29,
      "location_summary": "Homewood, Alabama • Phoenix, Arizona • Burbank, California + 25 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01221597"
    },
    {
      "nct_id": "NCT00550446",
      "title": "A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 386,
      "start_date": "2007-09",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2013-01-03",
      "last_synced_at": "2026-10-27T18:26:36.506Z",
      "location_count": 22,
      "location_summary": "Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00550446"
    },
    {
      "nct_id": "NCT04929483",
      "title": "Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "BIO89-100",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "89bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 222,
      "start_date": "2021-06-04",
      "completion_date": "2024-10-08",
      "has_results": true,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-10-27T18:26:36.506Z",
      "location_count": 88,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 68 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Madison",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04929483"
    },
    {
      "nct_id": "NCT06911359",
      "title": "The Effect and Safety of Anti-inflammatories and Dextrose Prolotherapy Injections in Treating Knee Osteoarthritis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Knee Osteoarthritis (OA)"
      ],
      "interventions": [
        {
          "name": "Participants are given Ibuprofen 400 mg to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.",
          "type": "DRUG"
        },
        {
          "name": "Participants are given a placebo to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Grant U.S. Air Force Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 68,
      "start_date": "2025-03-31",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-10-27T18:26:36.506Z",
      "location_count": 1,
      "location_summary": "Travis AFB, California",
      "locations": [
        {
          "city": "Travis AFB",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06911359"
    }
  ]
}